Legal & General Group Plc Increases Stock Holdings in United Therapeutics Corporation $UTHR

Legal & General Group Plc grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 198,519 shares of the biotechnology company’s stock after purchasing an additional 8,149 shares during the quarter. Legal & General Group Plc’s holdings in United Therapeutics were worth $57,044,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. HB Wealth Management LLC grew its position in shares of United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 35 shares during the last quarter. Park Avenue Securities LLC boosted its stake in United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 39 shares in the last quarter. Headlands Technologies LLC grew its holdings in shares of United Therapeutics by 1.5% during the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock worth $828,000 after purchasing an additional 40 shares during the last quarter. First Financial Bankshares Inc grew its holdings in shares of United Therapeutics by 0.3% during the first quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company’s stock worth $4,245,000 after purchasing an additional 42 shares during the last quarter. Finally, Nissay Asset Management Corp Japan ADV increased its position in shares of United Therapeutics by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,235 shares of the biotechnology company’s stock worth $1,614,000 after purchasing an additional 43 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on UTHR shares. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold 523,935 shares of company stock worth $226,780,697 over the last three months. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $485.77 on Wednesday. The firm’s fifty day moving average price is $443.02 and its 200 day moving average price is $358.73. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $486.20. The firm has a market cap of $20.92 billion, a price-to-earnings ratio of 18.41, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the firm earned $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.